Investors Bet Big on Cancer Drug Infant Duality Biologics and Its Rockstar Founder

Company has raised $120 million in 18 months from A-list investors including Eli Lilly and domestic heavyweight WuXi Biologics Key takeaways Duality Biologics’ new $90 million funding just 18 months after its founding comes on the reputation of its founder and focus on a hot cancer treatment area Recent advances in antibody-drug conjugates (ADCs) have led to an uptick in drug approvals and tide of similar new fundraising By Richard Barbarossa If one person’s reputation can form the foundation for building a company, then Dr. John Zhu, whose young cancer…

Read MORE »